Previous Close | 210.47 |
1-Year Change | 54.64% |
6-Months Change | -5.3% |
3-Months Change | -26.73% |
Moving Avg (50d) | 232.58 |
Moving Avg (200d) | 241.37 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 3.89B |
Beta (3-Years) | 0.79 |
Revenue Growth (ttm) | % |
Net Profit Margin (ttm) | % |
Return On Assets (ttm) | -145.96% |
EPS (ttm) | -19.24 |
PE Ratio (ttm) | -10.94 |
Dividend Yield | % |
Asset Description: | Madrigal Pharmaceuticals, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Strong sell |
Forecast Date: | 2024-10-10 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
214.679 | 220.994 | 225.203 | 231.517 | 242.041 | 252.564 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |